Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

74.22 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corp

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
From Incyte Corporation
Via Business Wire
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
From Incyte Corporation
Via Business Wire
Why Shares of MacroGenics Climbed Thursday
The cancer-focused biotech delivered a strong earnings report. 
Via The Motley Fool
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
From Incyte Corporation
Via Business Wire
Analyst Expectations for Incyte's Future
 
Via Benzinga
Incyte's Return On Capital Employed Overview
 
Via Benzinga
Which S&P 500 Stocks Look Most Attractive Now?
Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH. 
Via Talk Markets
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns
 
Via Benzinga
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
From Incyte
Via Business Wire
Analyst Ratings for Incyte
 
Via Benzinga
Earnings Outlook For Incyte
 
Via Benzinga
2 Steady Stocks to Buy in a Recession
Both companies are performing better than the broader market over the past year. 
Via The Motley Fool
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
From Incyte Corporation
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
From Incyte
Via Business Wire
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled. 
Via Investor's Business Daily
Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst
 
Via Benzinga
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
From Incyte
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
 
Via Benzinga
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before. 
Via Investor's Business Daily
7 Biotech Stocks That Will Make You Rich in 10 Years
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers
From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock... 
Via Talk Markets
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
From Incyte
Via Business Wire
Why These 7 Healthcare Stocks Could Soar in 2023
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023. 
Via InvestorPlace
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion
China Biopharma deal activity in 2022 was certainly slower than the previous year, but the ten largest deals, many of them booked in the second half of the year, totaled a decent $21.5 billion by... 
Via Talk Markets
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
These two biotechs are flying high right now. 
Via The Motley Fool
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
Cramer Says He's 'Always Liked' This Drug Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Oshkosh Corporation (NYSE: OSK) is a "slow grower. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.